• 1
    Fennerty MB. Review article: alternative approaches to the long-term management of GERD. Aliment Pharmacol Ther 2005; 22: 3944.
  • 2
    Inadomi JM, Fendrick AM. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol 2005; 3: 20815.
  • 3
    Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-esophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 34754.
  • 4
    Talley NJ, Venables TL, Green JR et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 85763.
  • 5
    Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 2004; 49: 9316.
  • 6
    Bytzer P, Blum A, de HD, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 1818.
  • 7
    Scholten T, Dekkers CP, Schutze K, Korner T, Bohuschke M, Gatz G. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. Digestion 2005; 72: 7685.
  • 8
    Kaspari S, Kupcinskas L, Heinze H, Berghofer P. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005; 17: 93541.
  • 9
    Dean BB, Gano AD, Knight K Jr, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 65664.
  • 10
    Lind T, Havelund T, Carlsson R et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 9749.
  • 11
    Nojkov B, Rubenstein JH, Adlis SA et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 47382.
  • 12
    Wu JC, Chan FK, Ching JY, Leung WK, Lee YT, Sung JJ. Empirical treatment based on “typical” reflux symptoms is inappropriate in a population with a high prevalence of Helicobacter pylori infection. Gastrointest Endosc 2002; 55: 4615.
  • 13
    Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45: II3742.
  • 14
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45: II437.
  • 15
    Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17280.
  • 16
    Whitehead WE, Corazziari E, Prizont R, Senior JR, Thompson WG, Veldhuyzen Van Zanten SJ. Definition of a responder in clinical trials for functional gastrointestinal disorders: report on a symposium. Gut 1999; 45: II7879.
  • 17
    Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 2001; 96: 290514.
  • 18
    Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98: 24549.
    Direct Link:
  • 19
    Zimmerman J, Hershcovici T. Bowel symptoms in nonerosive gastroesophageal reflux disease: nature, prevalence, and relation to acid reflux. J Clin Gastroenterol 2008; 42: 2615.
  • 20
    Frazzoni M, De ME, Zentilin P, Savarino V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004; 20: 818.
  • 21
    Shapiro M, Green C, Bautista JM et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006; 101: 108491.
    Direct Link:
  • 22
    Wu JC, Cheung CM, Wong VW, Sung JJ. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5: 6905.
  • 23
    Inadomi JM, Jamal R, Murata GH et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121: 1095100.
  • 24
    Whitehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, Turner M. Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006; 101: 105765.
    Direct Link:
  • 25
    Tack J, Caenepeel P, Arts J, Lee KJ, Sifrim D, Janssens J. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005; 54: 13706.
  • 26
    Farup PG, Hovde O, Torp R, Wetterhus S. Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern. Scand J Gastroenterol 1999; 34: 5759.
  • 27
    Holtmann G, Kutscher SU, Haag S et al. Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia; a randomized, double-blind placebo-controlled crossover study. Dig Dis Sci 2004; 49: 6729.
  • 28
    Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99: 9818.
    Direct Link:
  • 29
    Chen CL, Lin HH, Chen MC, Huang LC. Dyspeptic symptoms and water load test in patients with functional dyspepsia and reflux disease. Scand J Gastroenterol 2005; 40: 2832.
  • 30
    Lee KJ, Kim JH, Cho SW. Dyspeptic symptoms associated with hypersensitivity to gastric distension induced by duodenal acidification. J Gastroenterol Hepatol 2006; 21: 51520.
  • 31
    Lee KJ, Demarchi B, Demedts I, Sifrim D, Raeymaekers P, Tack J. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol 2004; 99: 176573.
    Direct Link:
  • 32
    Costantini M, Sturniolo GC, Zaninotto G et al. Altered esophageal pain threshold in irritable bowel syndrome. Dig Dis Sci 1993; 38: 20612.
  • 33
    Rubenstein JH, Nojkov B, Korsnes S et al. Esophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 44352.
  • 34
    Guillemot F, Ducrotte P, Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol 2005; 29: 2436.
  • 35
    Raftopoulos Y, Papasavas P, Landreneau R et al. Clinical outcome of laparoscopic antireflux surgery for patients with irritable bowel syndrome. Surg Endosc 2004; 18: 6559.